ライフサイエンスコーパス: aspergillosis

1 e in cancer), and Alp2 (a serine protease in aspergillosis).

2 hat 12/15-LOX is also active during invasive aspergillosis.

3 previously recognized to be at high risk of aspergillosis.

4 virulence in an experimental murine model of aspergillosis.

5 den in a neutropenic mouse model of invasive aspergillosis.

6 e the diagnosis of allergic bronchopulmonary aspergillosis.

7 CRI protocols in an animal model of invasive aspergillosis.

8 modulatory therapy to improve the outcome of aspergillosis.

9 se fungal rhinosinusitis or bronchopulmonary aspergillosis.

10 atus avirulent in a mouse model of pulmonary aspergillosis.

11 tive innate immune responses during invasive aspergillosis.

12 r in vitro or in a murine model of pulmonary aspergillosis.

13 8 eyes of 8 patients with isolated, orbital aspergillosis.

14 mprehension of the pathogenesis of pulmonary aspergillosis.

15 ausative agent of allergic broncho-pulmonary aspergillosis.

16 uated different case definitions of invasive aspergillosis.

17 vancement in the diagnosis and management of aspergillosis.

18 antibody detection for chronic and allergic aspergillosis.

19 for PTX3 SNPs modifying the risk of invasive aspergillosis.

20 remaining 165 patients no invasive pulmonary aspergillosis.

21 lent in a murine model of invasive pulmonary aspergillosis.

22 CGD mice from colitis and also from invasive aspergillosis.

23 ich remains the diagnostic gold standard for aspergillosis.

24 uced virulence in a murine model of invasive aspergillosis.

25 antification for early detection of invasive aspergillosis.

26 ransplant recipients with invasive pulmonary aspergillosis.

27 treatment failure in patients with invasive aspergillosis.

28 ithm judged 86 of 115 cases to have putative aspergillosis.

29 eria classified these as "probable" invasive aspergillosis.

30 unocompromised patients who develop invasive aspergillosis.

31 se of the more commonly encountered invasive aspergillosis.

32 pathology-controlled patients, 79 had proven aspergillosis.

33 spergillus fumigatus, the causative agent of aspergillosis.

34 Four patients had allergic bronchopulmonary aspergillosis.

35 asthma that mimics allergic bronchopulmonary aspergillosis.

36 causative agent of life-threatening invasive aspergillosis.

37 s fumigatus is responsible for most cases of aspergillosis.

38 tibility to postinfluenza invasive pulmonary aspergillosis.

39 isease (P: 0.05) increased the likelihood of aspergillosis.

40 uman antibodies in the sera of patients with aspergillosis.

41 tients with COVID-19 and suspected pulmonary aspergillosis.

42 ox15) are profoundly susceptible to invasive aspergillosis.

43 ed with patients not fulfilling criteria for aspergillosis.

44 and mortality in a murine model of invasive aspergillosis.

45 sive hyphae, disseminate, and cause invasive aspergillosis.

46 bits excessive lung inflammation in invasive aspergillosis.

47 fumigatus, the leading etiology of invasive aspergillosis.

48 ient mice in a neutropenic model of invasive aspergillosis.

49 ungal virulence in a mouse model of invasive aspergillosis.

50 nd, in turn, host susceptibility to invasive aspergillosis.

51 colonization, and allergic bronchopulmonary aspergillosis.

52 potential source of azole-resistant invasive aspergillosis.

53 detrimental immunopathology that is seen in aspergillosis.

54 in patients with triazole-resistant invasive aspergillosis.

55 hogenic fungus Aspergillus fumigatus, called aspergillosis.

56 ificant challenge in effective management of aspergillosis.

57 The incidence was 26.7% (14.1% aspergillosis, 12.6% yeast infections).

58 ), 79 patients had proven invasive pulmonary aspergillosis (15.1%).

59 e inflammasome provides host defence against aspergillosis(2,3), which is a major health concern for

60 lable for follow-up (one patient died of CNS aspergillosis 29 d after RLT and another of sepsis in ap

61 gorithm judged 199 patients to have putative aspergillosis (38.0%) and 246 to have Aspergillus coloni

62 udy Group criteria, 32 patients had probable aspergillosis (6.1%) and 413 patients were not classifia

63 Of 34 patients with orbital aspergillosis, 8 (23.5%) had isolated orbital involvemen

64 igatus) is the most common cause of invasive aspergillosis, a frequently fatal lung disease primarily

65 e displayed high susceptibility to pulmonary aspergillosis, a phenotype associated with a proinflamma

66 Aspergillus fumigatus causes invasive aspergillosis, a potentially fatal infection in oncohema

67 o the diagnosis of allergic bronchopulmonary aspergillosis (ABPA) and fungal sensitisation, but how t

68 g diseases such as allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensi

69 ng to discriminate allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF).

70 illosis (CCPA) and allergic bronchopulmonary aspergillosis (ABPA) in overtly immunocompetent and atop

71 Allergic bronchopulmonary aspergillosis (ABPA) is caused by A fumigatus and is cha

72 Allergic bronchopulmonary aspergillosis (ABPA) is characterized by an allergic imm

73 Although allergic bronchopulmonary aspergillosis (ABPA) leads to deterioration of pulmonary

74 nsitization and/or allergic bronchopulmonary aspergillosis (ABPA), which affects pulmonary function a

75 (CF) patients with allergic bronchopulmonary aspergillosis (ABPA).

76 mmunity result in increased risk of invasive aspergillosis after chemotherapy or transplantation.

77 were shown to influence the risk of invasive aspergillosis among hematopoietic stem cell transplant r

78 valuated the incidence of invasive pulmonary aspergillosis among intubated patients with critical cor

79 Incidences of invasive pulmonary aspergillosis, an infection caused predominantly by Aspe

80 r study involving 107 patients with invasive aspergillosis and 223 matched controls.

81 ts were tested for allergic bronchopulmonary aspergillosis and 82 patients had been tested for immuno

82 treatment-related deaths from AEs, influenza/aspergillosis and adenovirus-related hepatitis.

83 de invasive aspergillosis, chronic pulmonary aspergillosis and bronchitis.

84 y type I confer a predisposition to invasive aspergillosis and candidiasis.

85 fungal disease (IFD), particularly invasive aspergillosis and candidiasis.

86 f TLR3 was associated with susceptibility to aspergillosis and concomitant failure to activate memory

87 se of allergic rhinosinusitis, postoperative aspergillosis and fungal keratitis.

88 multiplex real-time PCR capable of detecting aspergillosis and genetic markers associated with azole

89 ion into account, reliably detected invasive aspergillosis and may be a promising diagnostic tool for

90 gets for the treatment of invasive pulmonary aspergillosis and may potentiate both innate immunity an

91 It is approved for the treatment of invasive aspergillosis and mucormycosis.

92 Invasive aspergillosis and other fungal infections occur in immun

93 Rare instances of aspergillosis and other mycoses, including agents of muc

94 more, nosocomial infections such as invasive aspergillosis and Pseudomonas aeruginosa occurred during

95 gnostic differences between tracheobronchial aspergillosis and pulmonary aspergillosis without trache

96 highlights the magnitude of azole-resistant aspergillosis and resistance mechanisms implicated in th

97 ood conditions are allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitizatio

98 spergillus include allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitizatio

99 seen, and 1 trial indicated a lower rate of aspergillosis and survival benefits in patients with AML

100 Enterobacter bacteremia, invasive aspergillosis, and disseminated Candida infections were

101 lammatory response during invasive pulmonary aspergillosis, and in particular the IL-1 axis, drives t

102 chondrial respiration in the pathogenesis of aspergillosis, and lay the foundation for future researc

103 of asthma, croup, allergic bronchopulmonary aspergillosis, and subglottic hemangioma.

104 , the use of molecular (PCR) diagnostics for aspergillosis, and the crucial role of antibody detectio

105 med, radiology data consistent with invasive aspergillosis, and the timing of initiation of antifunga

106 ective in reducing the incidence of invasive Aspergillosis as compared with no prophylaxis.

107 proven or probable IA from patients without aspergillosis, as determined by European Organization fo

108 is particularly true for invasive pulmonary aspergillosis, as so far, sources of (macro)elements tha

109 We developed invasive aspergillosis (Aspergillus fumigatus) and mucormycosis (

110 e of IFD, invasive candidiasis, and invasive aspergillosis at 1 year.

111 and validate novel methods for diagnosis of aspergillosis based on detection of galactomannan requir

112 patients without allergic broncho-pulmonary aspergillosis but sensitized to A. fumigatus and in nine

113 vaccine-induced protection from experimental aspergillosis, but the molecular mechanisms leading to t

114 as the potential to improve the diagnosis of aspergillosis by offering more rapid and sensitive ident

115 assified as coronavirus associated pulmonary aspergillosis (CAPA) according to previous consensus def

116 COVID-19-associated pulmonary aspergillosis (CAPA) was recently reported as a potentia

117 Invasive aspergillosis carries a high mortality with a rising pre

118 This is the first description of canine aspergillosis caused by A. versicolor.

119 Invasive aspergillosis caused by triazole-resistant strains of As

120 Invasive pulmonary aspergillosis causes substantial mortality in immunocomp

121 fumigatus causes chronic cavitary pulmonary aspergillosis (CCPA) and allergic bronchopulmonary asper

122 4 CPA patient sera collected at the National Aspergillosis Centre (Manchester, United Kingdom) and co

123 tiple pulmonary diseases, including invasive aspergillosis, chronic necrotizing aspergillosis, fungal

124 atus may result in allergic bronchopulmonary aspergillosis, chronic necrotizing pulmonary aspergillos

125 s of Aspergillus infections include invasive aspergillosis, chronic pulmonary aspergillosis and bronc

126 During aspergillosis, circulating pDCs entered the lung in resp

127 tive GM (serologic allergic bronchopulmonary aspergillosis); class 3 (n = 19, 14.6%) represented pati

128 From 2014-2019, invasive pulmonary aspergillosis complicated 7.2% (0-23.1% in different inf

129 Development of invasive aspergillosis correlates with impairments in innate immu

130 Chronic pulmonary aspergillosis (CPA) is an infectious disease that progre

131 is critical to diagnosing chronic pulmonary aspergillosis (CPA).

132 CMC, invasive candidiasis, invasive aspergillosis, deep dermatophytosis, pneumocystosis, and

133 ves survival of mice with invasive pulmonary aspergillosis, demonstrating the potential of CalA as an

134 The calibrator can be used to standardize aspergillosis diagnostic assays which detect and/or quan

135 In invasive pulmonary aspergillosis, direct invasion and occlusion of pulmonar

136 ortunistic animal and human pathogen causing aspergillosis diseases with incidence increasing in the

137 A case of fatal aspergillosis due to a TR46/Y121F/T289A azole-resistant

138 Eight patients presented with invasive aspergillosis due to TR46/Y121F/T289A, and treatment fai

139 tis, and a new immunologic classification of aspergillosis emerged.

140 Secondary outcomes were invasive aspergillosis, empirical antifungal therapy, and overall

141 , pneumonia, secondary peritonitis, invasive aspergillosis, endocarditis and myocardial infarction.

142 In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against

143 gatus is the most frequent agent of invasive aspergillosis, followed by A. lentulus and A. viridinuta

144 h a potentially low pretest risk of invasive aspergillosis following effective antimold prophylaxis.

145 son clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole w

146 elped distinguish allergic broncho-pulmonary aspergillosis from A. fumigatus sensitization with good

147 nts with influenza associated with pulmonary aspergillosis from three hospital ICUs between 2010 and

148 s is still limited, mouse models of invasive aspergillosis fulfill a critical void for studying treat

149 invasive aspergillosis, chronic necrotizing aspergillosis, fungal colonization, and allergic broncho

150 Management of invasive aspergillosis has been improved by biomarker assays, but

151 Invasive aspergillosis has emerged as an important cause of morbi

152 Patients with invasive aspergillosis (IA) (3/3) had positive GM at baseline as

153 To investigate risk factors for invasive aspergillosis (IA) after kidney transplantation (KT), we

154 U) patients with probable or proven invasive aspergillosis (IA) and 100 ICU patients without IA.

155 211 samples from 10 proven/probable invasive aspergillosis (IA) and 2 possible IA cases and 27 contro

156 clinical cases from colonization of invasive aspergillosis (IA) and major building construction.

157 Outbreaks of invasive aspergillosis (IA) are believed to be caused by airborne

158 apy (cART), roughly 50% of cases of invasive aspergillosis (IA) associated with human immunodeficienc

159 Strict definition of invasive aspergillosis (IA) cases is required to allow precise co

160 NA extracts from 14 proven/probable invasive aspergillosis (IA) cases, 2 possible IA cases, and 33 co

161 The outcome of invasive aspergillosis (IA) continues to be associated with signi

162 Delayed diagnosis in invasive aspergillosis (IA) contributes to its high mortality.

163 Screening of high-risk patients for invasive aspergillosis (IA) has the potential to decrease the use

164 gies for the molecular detection of invasive aspergillosis (IA) have been established by the European

165 the early diagnosis and therapy of invasive aspergillosis (IA) in high-risk hematological patients r

166 ng is increasingly used to diagnose invasive aspergillosis (IA) in high-risk patients.

167 iquitous mold, is a common cause of invasive aspergillosis (IA) in immunocompromised patients.

168 The most common cause of invasive aspergillosis (IA) in patients with chronic granulomatou

169 Despite suffering an outbreak of invasive aspergillosis (IA) in the intensive care unit due to ext

170 Invasive aspergillosis (IA) is a life-threatening complication am

171 Invasive aspergillosis (IA) is a life-threatening infection for i

172 Invasive aspergillosis (IA) is a life-threatening systemic fungal

173 Invasive aspergillosis (IA) is a significant cause of morbidity a

174 Invasive aspergillosis (IA) is an important cause of morbidity an

175 Invasive aspergillosis (IA) is associated with poor outcomes in p

176 A lung transplant patient with invasive aspergillosis (IA) manifested symptoms of voriconazole-i

177 The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence of diseas

178 Invasive aspergillosis (IA) remains a leading cause of morbidity

179 Invasive aspergillosis (IA) remains a leading cause of mortality

180 Diagnosis of invasive aspergillosis (IA) remains challenging.

181 Invasive aspergillosis (IA) resulting from infection by Aspergill

182 s a rapid test for the diagnosis of invasive aspergillosis (IA) that has been almost exclusively eval

183 ansplant recipients are at risk for invasive aspergillosis (IA), associated with a significant mortal

184 otizing pulmonary aspergillosis, or invasive aspergillosis (IA), depending on the host's immune statu

185 long been used for the diagnosis of invasive aspergillosis (IA), variable performance in clinical pra

186 in neutropenic mice with invasive pulmonary aspergillosis (IA).

187 idely utilized for the diagnosis of invasive aspergillosis (IA).

188 vity threshold for the diagnosis of invasive aspergillosis (IA).

189 istance is an increasing problem in invasive aspergillosis (IA).

190 phylaxis trials have shown trends of reduced aspergillosis in BMT patients; however, no survival bene

191 Three distinct classes of aspergillosis in CF were identified by latent class anal

192 established serologic markers, to reclassify aspergillosis in CF.

193 he presentation and epidemiology of invasive aspergillosis in children and adolescents with acquired

194 ncreasing number of small studies describing aspergillosis in COVID-19 patients with severe respirato

195 y tract colonization from invasive pulmonary aspergillosis in critically ill patients.

196 Disseminated aspergillosis in dogs has been associated with Aspergill

197 were used to generate a mechanism to define aspergillosis in future COVID-19 patients.

198 re, we evaluated susceptibility to pulmonary aspergillosis in globally NADPH oxidase-deficient mice v

199 iciency is a novel susceptibility factor for aspergillosis in high-risk patients.

200 l pathogen causing life-threatening invasive aspergillosis in immunocompromised patients.

201 mAb treatment is protective during invasive aspergillosis in neutropenic mice.

202 s and may contribute to the risk of invasive aspergillosis in patients treated with HSCT.

203 of great value in the clearance of invasive aspergillosis in patients with CGD.

204 in order of importance after candidiasis and aspergillosis in patients with hematological and allogen

205 The low pretest risk of invasive aspergillosis in the context of effective antimold proph

206 insights into the pathogenesis of pulmonary aspergillosis in the immunocompromised host.

207 competent host but can cause lethal invasive aspergillosis in the immunocompromised host.

208 ential mechanism for development of invasive aspergillosis in the setting of CGD and corticosteroid-i

209 olonization from putative invasive pulmonary aspergillosis in this patient group.

210 to improve clinical outcomes associated with aspergillosis in vulnerable patient populations.

211 t severe clinical form of invasive pulmonary aspergillosis in which the fungal infection is entirely

212 he performance of any PCR assay for invasive aspergillosis in whole blood or serum and that used the

213 ns expanded in patients with active invasive aspergillosis, indicating their contribution to infectio

214 ogeny of adaptive immune responses to murine aspergillosis infection in relation to vaccination.

215 t toxicity, including pulmonary and cerebral aspergillosis infections.

216 e related to diagnosis of invasive pulmonary aspergillosis, invasive candidiasis, and the common ende

217 s and optimal therapy for invasive pulmonary aspergillosis (IPA) after kidney transplantation (KT) re

218 Risk factors for invasive pulmonary aspergillosis (IPA) after kidney transplantation have be

219 ng the study period, with invasive pulmonary aspergillosis (IPA) complicating 6.8% of ISA, 1.3% of PO

220 y on an LFD developed for invasive pulmonary aspergillosis (IPA) detection.

221 Invasive pulmonary aspergillosis (IPA) has dire consequences in hemato-onco

222 Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease c

223 Invasive pulmonary aspergillosis (IPA) is a significant cause of morbidity

224 Invasive pulmonary aspergillosis (IPA) is a significant complication after

225 olved inflammation during invasive pulmonary aspergillosis (IPA) is associated with a poor outcome.

226 Invasive pulmonary aspergillosis (IPA) is one of the major complications in

227 the causative organism in invasive pulmonary aspergillosis (IPA) is recommended.

228 Invasive pulmonary aspergillosis (IPA) is the most common manifestation, so

229 Diagnosis of invasive pulmonary aspergillosis (IPA) remains a major challenge to clinica

230 Invasive pulmonary aspergillosis (IPA) remains an important cause of morbid

231 ndard test for diagnosing invasive pulmonary aspergillosis (IPA).

232 al immunity in a model of invasive pulmonary aspergillosis (IPA).

233 gent for the treatment of invasive pulmonary aspergillosis (IPA).

234 to therapeutic failure in invasive pulmonary aspergillosis (IPA).

235 Invasive aspergillosis is a deadly infection for which new antifu

236 Invasive aspergillosis is a difficult-to-diagnose infection with

237 Invasive pulmonary aspergillosis is a leading cause of infection-associated

238 Invasive pulmonary Aspergillosis is a leading cause of morbidity and mortal

239 Pulmonary aspergillosis is a lethal mold infection in the immunoco

240 Invasive aspergillosis is a life-threatening complication of neut

241 Invasive aspergillosis is a major threat to patients with chronic

242 Invasive aspergillosis is a serious infectious complication after

243 Diagnosis of invasive aspergillosis is challenging and delays in treatment are

244 Invasive aspergillosis is often a consequence of immune suppressi

245 Allergic bronchopulmonary aspergillosis is often difficult to treat and results in

246 Allergic bronchopulmonary aspergillosis is one of the most severe A. fumigatus-rel

247 hough the number of cases of azole-resistant aspergillosis is still limited, resistance mechanisms co

248 the strategies to improve the management of aspergillosis is the adoptive transfer of antigen-specif

249 SNPs) in PTX3 to the development of invasive aspergillosis is unknown.

250 Rationale: Invasive tracheobronchial aspergillosis (ITBA) is an uncommon but severe clinical

251 own by direct visualization in our zebrafish aspergillosis model in vivo.

252 angiogenesis in a murine invasive pulmonary aspergillosis model.

253 D-1) blockade in a murine invasive pulmonary aspergillosis model.

254 icacious in the prophylaxis and treatment of aspergillosis, mucormycosis, and other invasive fungal i

255 Bronchopulmonary aspergillosis (n = 16), severe asthma with fungal sensit

256 Allergic bronchopulmonary aspergillosis occurs almost exclusively in cystic fibros

257 Allergic bronchopulmonary aspergillosis (odds ratio [OR], 2.66; P = 5.0 x 10-8), a

258 e in patients with allergic bronchopulmonary aspergillosis or cystic fibrosis are among the major rec

259 aspergillosis, chronic necrotizing pulmonary aspergillosis, or invasive aspergillosis (IA), depending

260 vered 6 clinical isolates from patients with aspergillosis originally identified as Aspergillus nidul

261 burdens in a rat model of invasive pulmonary aspergillosis (p<0.05) compared to treatment with the ca

262 as compared with putative invasive pulmonary aspergillosis (PIPA).

263 During invasive aspergillosis, platelets might be involved in immune def

264 e mortality and morbidity caused by invasive aspergillosis present a major obstacle to the successful

265 The diagnosis of allergic bronchopulmonary aspergillosis relies on criteria first established in 19

266 Diagnosis of invasive aspergillosis remains a significant problem.

267 rent available assays, diagnosis of invasive aspergillosis remains challenging.

268 ly immunosuppressed murine model of invasive aspergillosis resulted in hypovirulence, while analysis

269 rve as an S source during invasive pulmonary aspergillosis since a sulfate transporter mutant strain

270 ocomial infections including candidiasis and aspergillosis, some of which display reduced susceptibil

271 In a murine model of aspergillosis, the Deltagna1 mutant strain exhibited att

272 Unlike invasive aspergillosis, the prognosis and outcome of hematologic

273 f PCR in the diagnosis of invasive pulmonary aspergillosis, the role of beta-d-glucan assays in the d

274 and for the diagnosis of invasive pulmonary aspergillosis, the role of PCR in the diagnosis of invas

275 ection for cryptococcal disease and invasive aspergillosis, the use of molecular (PCR) diagnostics fo

276 Isolated orbital aspergillosis, though rare, should be considered in the

277 ine patients with allergic broncho-pulmonary aspergillosis (two with cystic fibrosis and seven with a

278 therapeutic decisions when treating invasive aspergillosis using changes in biomarkers as a surrogate

279 igatus and unique susceptibility to invasive aspergillosis via incompletely characterized mechanisms.

280 ive incidence of proven or probable invasive aspergillosis was 0.5% (95% CI, 0.1%-3.5%) with caspofun

281 The incidence of breakthrough invasive aspergillosis was 1.9% (5/262), all with true-positive G

282 Invasive pulmonary aspergillosis was an independent risk factor for 1-year

283 Probable/proven aspergillosis was associated with a significantly higher

284 Invasive pulmonary aspergillosis was defined according to European Organiza

285 Probable or proven invasive pulmonary aspergillosis was diagnosed in 14% of our study populati

286 Aspergillosis was linked to BTK-dependent fungal immunit

287 Increased aspergillosis was observed with ibrutinib monotherapy an

288 and leucopenic mice, the outcome of invasive aspergillosis was similar to that described for A. fumig

289 es and specificities for diagnosing invasive aspergillosis were 81.6% and 91.6%, and 76.9% and 89.4%,

290 , malignant organ infiltration, and invasive aspergillosis were associated with higher hospital morta

291 the ICU with severe influenza and pulmonary aspergillosis were included.

292 tal fungus that can cause invasive pulmonary aspergillosis when spores are inhaled into the respirato

293 isease, and postinfluenza invasive pulmonary aspergillosis, which is becoming a well-recognized clini

294 spergillus, beyond allergic bronchopulmonary aspergillosis, which require classification.

295 nt sensitivity for the screening of invasive aspergillosis while maintaining methodological simplicit

296 tremely susceptible to mucormycosis, but not aspergillosis, while sodium bicarbonate reversed this su

297 nt screening protocol for invasive pulmonary aspergillosis with bronchoalveolar lavage galactomannan

298 tracheobronchial aspergillosis and pulmonary aspergillosis without tracheobronchial lesions among pat

299 lucan concentrations than invasive pulmonary aspergillosis without tracheobronchial lesions.

300 avus is the second leading cause of invasive aspergillosis worldwide.